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Abstract
Introduction: There is paucity of data related to potential gender differences in the use of interventions to prevent and treat
cardiovascular disease (CVD) among HIV-positive individuals. We investigated whether such differences exist in the observa-
tional D:A:D cohort study.
Methods: Participants were followed from study enrolment until the earliest of death, six months after last visit or February
1, 2015. Initiation of CVD interventions [lipid-lowering drugs (LLDs), angiotensin-converting enzyme inhibitors (ACEIs), anti-hy-
pertensives, invasive cardiovascular procedures (ICPs) were investigated and Poisson regression models calculated whether
rates were lower among women than men, adjusting for potential confounders.
Results: Women (n = 12,955) were generally at lower CVD risk than men (n = 36,094). Overall, initiation rates of CVD inter-
ventions were lower in women than men; LLDs: incidence rate 1.28 [1.21, 1.35] vs. 2.40 [2.34, 2.46]; ACEIs: 0.88 [0.82, 0.93]
vs. 1.43 [1.39, 1.48]; anti-hypertensives: 1.40 [1.33, 1.47] vs. 1.72 [1.68, 1.77] and ICPs: 0.08 [0.06, 0.10] vs. 0.30 [0.28, 0.32],
and this was also true for most CVD interventions when exclusively considering periods of follow-up for which individuals
were at high CVD risk. In fully adjusted models, women were less likely to receive CVD interventions than men (LLDs: relative
rate 0.83 [0.78, 0.88]; ACEIs: 0.93 [0.86, 1.01]; ICPs: 0.54 [0.43, 0.68]), except for the receipt of anti-hypertensives (1.17
[1.10, 1.25]).
Conclusion: The use of most CVD interventions was lower among women than men. Interventions are needed to ensure that
all HIV-positive persons, particularly women, are appropriately monitored for CVD and, if required, receive appropriate CVD
interventions.
Keywords: Cardiovascular disease; gender; cardiovascular disease interventions; cohort studies; HIV; women; myocardial
infarction; stroke
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1 | INTRODUCTION
HIV-positive individuals are known to be at increased risk of
cardiovascular disease (CVD) compared to the general popula-
tion [1,2], partly due to an increased prevalence of some CVD
risk factors, exposure to some antiretroviral drugs and chronic
immune activation [3–7]. Previous findings also indicate that
HIV-infection has a slightly greater impact on the risk of
myocardial infarction (MI) and stroke in women compared to
men [2–4,8,9].
In the general population, it is recognized that the risk of
CVD, including MI and stroke, increases with age, and that
women are less likely to develop CVD at any given age than
men [10–14]. However, this gender gap in cardiovascular
morbidity diminishes with increasing age, as the protective
effect of oestrogen wanes post-menopause resulting in an
increase in CVD morbidity in women [10–16]. Although
there have been substantial reductions in the incidence of
MI and improvements in survival after MI and stroke over
the last two decades [16–18], these improvements have
lagged behind in women compared to men [16,19–21]. In
particular, women have been shown to have higher in-hospi-
tal mortality after MI at a younger age than men [22–27], as
well as higher rates of complications and mortality after inva-
sive coronary interventions [28,29]. Evidence also indicates
that women experience more severe stroke events, longer
hospital stays and higher mortality rates following a stroke
compared to men [16].
The reasons for these poorer outcomes remain unclear, but
it is likely that multiple factors play a role, both before and
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after an event. Importantly, there is increasing evidence of
delayed or less intensive use of medical and invasive proce-
dures for diagnostic evaluation and treatment of MI and
stroke among women compared to men [11,12,16,20,30–34].
A previous study in the general population also demonstrated
an inverse association between in-hospital mortality after MI
and the number of CVD risk factors that were present in an
individual [35]. This suggests that some individuals at appar-
ently low CVD risk may have other, as yet unidentified, under-
lying risk factors or pathophysiological features that result in
an MI of greater severity, a poorer prognosis and/or less opti-
mal medical management. This hypothesis may pertain particu-
larly to women, as they are generally perceived to be at lower
risk of CVD, particularly if pre-menopausal.
As in the general population, guidelines for the prevention
of CVD among HIV-positive individuals generally focus on
groups at high CVD risk [36–38]. Since women are generally
considered to be at low CVD risk, it may be that the poorer
outcomes in low risk individuals observed in the general pop-
ulation [35] may take on greater relevance among HIV-posi-
tive women who are generally at higher overall risk of MI
and stroke due to their HIV status [2–4,7–9]. An under-
standing of the use of interventions to prevent and treat
CVD in HIV-positive women compared to men is therefore
required. The aim of this study was to investigate potential
gender differences in the use of CVD-related interventions
in the large, prospective Data on Adverse effects of
antiretroviral Drugs (D:A:D) study.
2 | METHODS
The D:A:D study is a large, prospective cohort study which
follows >49,000 HIV-positive persons from 11 collaborating
cohorts in Europe, USA and Australia, contributing to
>430,000 person years of follow-up (PYRS). The details of
the study have been described previously [6]. The data are
obtained prospectively with information collected on demo-
graphic factors, AIDS events, CD4 counts, HIV RNA viral
loads, other laboratory test results (e.g. total cholesterol
(TC), triglycerides (TG)), antiretroviral therapy-regimen and
treatment history, CVD risk factors and treatments. Data on
clinical endpoints including non-fatal/fatal MIs, strokes, deaths
(including sudden cardiac death), and invasive cardiovascular
procedures (ICPs; including coronary artery bypass grafts
(CABGs), angioplasties and carotid endarterectomies) are
reported to the D:A:D coordinating centre via designated
case report forms and centrally validated according to stan-
dardized algorithms (https://www.chip.dk/Portals/0/files/Study
%20documents/DAD_MOOP_revised2013.pdf). MIs are classi-
fied with a Dundee score using criteria from the WHO
MONICA Study [39] and stroke events are validated on the
basis of the presence of focal neurological signs with dura-
tion > 24 hours with no evidence of any non-vascular cause.
Causes of death are classified using the Coding of Causes of
Death (CoDe) methodology, developed for the classification
of causes of death in HIV-positive persons (www.chip.dk/c
ode) [40]. This analysis was conducted in accordance with
the Declaration of Helsinki, with approval by national ethics
committees and informed consent where required by
national regulations.
2.1 | Statistical methods
Men and women were followed from baseline (date of entry
into the D:A:D study which occurred on or after February 1,
1999) until the earliest of death, six months after last visit or
February 1, 2015. CVD interventions considered were ICPs
and the use of anti-hypertensives, angiotensin-converting
enzyme inhibitors (ACEIs) and lipid lowering drugs (LLDs).
Individuals with a previous MI/stroke at baseline (i.e. prior to
D:A:D Study entry (n = 654)) were excluded from analyses of
the subsequent initiation of interventions as the interventions
received by these individuals prior to and after the event
could not be ascertained with sufficient accuracy. Rates of ini-
tiation of each CVD-related intervention were calculated for
the total time of follow-up and for the specific periods of fol-
low-up during which individuals were at high CVD risk accord-
ing to one or more of the following risk subgroups: TC
>6.2 mmol/L (>240 mg/dl), TG >2.3 mmol/L (>204 mg/dl),
hypertension (systolic blood pressure (SBP) >140 mmHg, dias-
tolic blood pressure (DBP) >90 mmHg, or reported use of
ACEIs/anti-hypertensives), previous (post baseline) MI, dia-
betes (two consecutive fasting blood glucoses >7.0 mmol/L,
HbA1C >6.5% or anti-diabetic treatment), age >50 years or
predicted 10-year CVD risk score >10% (moderate/high
Framingham CVD risk score). As the D:A:D CVD risk score
was published in more recent years, the Framingham risk
score was chosen as it has been more widely used in partici-
pating clinics over the whole study period. Since ACEIs may
also be used to treat hypertension, consideration of ACEIs
separately to other anti-hypertensives may result in an under-
estimation of drugs used to treat hypertension. Thus, we addi-
tionally considered a combined drug classification of either
ACEIs or other anti-hypertensives.
Each individual’s follow-up was split into a series of consec-
utive one-month periods and the clinical, immunologic and
virologic status at the start of each period was established.
Poisson regression models were then used to assess whether
initiation rates of CVD interventions were lower in women
compared to men, after adjustment for the following potential
time-updated confounders: age, calendar year, body mass
index (BMI), TC, TG, hypertension, previous MI, race, smoking
status, AIDS, CVD family history, stroke, diabetes and CVD
risk score >10%.
For each calendar year of follow-up, an individual was con-
sidered to have been monitored for TC, TG, HDL and SBP/
DBP if there was at least one measure of each within that
year. Logistic regression models then assessed whether the
probability of being monitored for each measure differed in
men and women, after adjustment for calendar year, age, BMI,
TC, TG, hypertension, previous MI, diabetes and CVD risk
score >10%.
Additional analyses were performed in which we adjusted
for TC, TG and SBP/DBP as continuous rather than categori-
cal covariates and after excluding those with a mode of HIV
acquisition other than heterosexual sex, as the latter is the
group in which the comparison between men and women is
least affected by other, unmeasured confounders. Where dif-
ferences between men and women were identified we fitted a
series of regression models, progressively adjusting for each
of the potential confounders, allowing us to identify the poten-
tial mediators of any differences seen. Finally, since our main
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analyses investigated overall initiation rates both before and
after an MI, we performed sensitivity analyses in which
post-MI follow up was censored, thus restricting analyses to
interventions used only prophylactically and allowing us to
investigate whether findings were consistent.
3 | RESULTS
3.1 | Characteristics at baseline and at time of MI
Of the 49,049 included participants, 12,955 were women and
36,094 were men. Baseline characteristics of the men and
women at study entry are shown in Table 1. Most women
acquired HIV through heterosexual transmission (9037
(69.8%)), whereas most men acquired HIV through sex with
men (21491 (59.5%)). Compared to men, the women were
significantly more likely to be younger (median age [interquar-
tile range (IQR)] 34 [29,40] vs. 39 [33,41] years), more likely
of black African race (2610 (20.2%) vs. 2220 (6.2%)), less
likely to be current smokers (3814 (29.4%) vs. 13556
(37.6%)) or ex-smokers (1841 (14.2%) vs. 6465 (17.9%)), and
less likely to have other traditional CVD risk factors such as
diabetes, hypertension, dyslipidemia, previous ICP or receipt
of LLDs and ACEIs (Table 1). Furthermore, a higher propor-
tion of women had a low Framingham CVD risk score (<10%),
with smaller proportions belonging to the moderate (10-20%)
and high (>20%) CVD risk groups. A slightly higher proportion
of women than men had an unknown CVD risk score
(Table 1).
3.2 | Periods of follow-up at high CVD risk
The women in the study contributed a total of 113,821 PYRS
to the analyses. Of these, 14.9% were contributed by women
with a high TG level, 17.5% were contributed by women
>50 years, and 16.9% were contributed by women with
hypertension (Table 2). The men in the study contributed a
total of 314,843 PYRS to the analyses. A higher proportion of
this follow-up time was contributed by men with high TG
(29.3%), age >50 years (31.7%) and hypertension (23.8%).
Only 4.4% of follow-up time in women was contributed by
women with an established moderate/high CVD risk score
(>10%) compared to 27.5% of follow-up time in men.
3.3 | Rates of monitoring for CVD risk factors
Absolute rates of monitoring for TC, TG, HDL-C and blood
pressure within any 12 month period in both low and high
CVD risk subgroups of the participants were similar in women
and men; TC: 80.3% vs. 81.7%; TG: 76.9 vs. 79.2%; HDL-C:
64.0 vs 65.3% and blood pressure: 66.6 vs. 65.8%. In unad-
justed analyses, women were slightly less likely to be moni-
tored for TC, TG and HDL-C (TC: odds ratio 0.92 [0.89, 0.96];
TG: 0.88 [0.79, 0.97]; HDL-C 0.95 [0.88, 1.02]), although dif-
ferences were attenuated and became non-significant in
adjusted models (TC: 1.01 [0.98, 1.05]; TG: 0.97 [0.93, 1.01];
HDL-C: 1.03 [0.96, 1.10]). In contrast, while no difference in
blood pressure monitoring rates were seen prior to adjust-
ment (0.99 [0.93, 1.05]), women were more likely to be moni-
tored for blood pressure in adjusted models (1.12 [1.08,
1.15]).
3.4 | Use of CVD interventions
Over the total follow-up period, 1334 (10.3%) women
and 6274 (17.4%) men initiated LLD; 944 (7.3%) women and
4016 (11.1%) men initiated ACEIs; 1444 (11.1%) women
and 4834 (13.4%) men initiated anti-hypertensives; 1715
(13.2%) women and 6126 (17.0%) men initiated ACEIs or
anti-hypertensives; and 89 (0.7%) women and 932 (2.6%)
men underwent an ICP. When taking all follow-up time into
consideration, women had lower initiation rates than men for
all CVD interventions: LLDs (incidence rate (IR) [95% CI]/
100 PYRS in women vs. men 1.28 [1.21, 1.35] vs. 2.40
[2.34, 2.46]), ACEIs (0.88 [0.82, 0.93] vs. 1.43 [1.39, 1.48]),
anti-hypertensives (1.40 [1.33, 1.47] vs. 1.72 [1.68, 1.77]);
ACEIs or anti-hypertensives 1.59 [1.61, 1.77] vs. 2.26 [2.21,
2.32] and ICPs (0.08 [0.06, 0.10] vs. 0.30 [0.28, 0.32]) (Fig-
ure 1).
When restricting the analysis only to periods of follow-up
during which an individual was in one of the high CVD risk
subgroups, women generally continued to have lower initia-
tion rates than men for most CVD interventions (Table 3).
The only exceptions to this were for the receipt of LLDs,
ACEIs, anti-hypertensives and ACEIs or anti-hypertensives in
people with a CVD risk score >10%; the uptake of anti-hy-
pertensives and ACEIs or anti-hypertensives among people
with hypertension and the receipt of ACEIs among people
with a previous MI. In each of these latter subgroups, initia-
tion rates of the interventions were higher in women than
men (Table 3).
3.5 | Poisson regression models
In Poisson regression models, unadjusted rates of initiation
for each of the four CVD interventions (LLDs, ACEIs, anti-
hypertensives and ICPs) were lower in women than in men
(Figure 2). When adjusting for potential confounders, rate
ratios were attenuated but still indicated significantly lower
initiation rates in women compared to men for LLDs and
ICPs: LLDs: (relative rate (RR)) 0.83 [0.78, 0.88]; ICPs: 0.54
[0.43, 0.68], and borderline significantly lower rates for
ACEIs (0.93 [0.86, 1.01]). For anti-hypertensives, the direc-
tion of the association was reversed after adjustment for
potential confounders, reflecting a higher initiation rate in
women compared to men (1.17 [1.10, 1.25]) (Figure 2). This
was also observed when we considered initiation of either
anti-hypertensives or ACEIs (1.08 [1.02, 1.15]). To investigate
which factors were likely to contribute to the higher likeli-
hood of use of anti-hypertensives by women compared to
men, a series of regression models was fitted in which we
progressively adjusted for each of the potential confounders
in turn. This analysis revealed that this finding was mainly
driven by adjustments for hypertension and a CVD risk
score >10%.
Additional adjustment for TC, TG, and SBP/DBP as
continuous covariates, and the exclusion of those with modes
of HIV transmission other than heterosexual sex, led to
consistent results. Consistent results were also observed
when follow-up was censored at the time of an MI, suggest-
ing that our findings could not simply be explained by a
higher uptake of secondary prevention interventions post-MI
in men.
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Table 1. Comparison of characteristics of men and women at D:A:D Study enrolment
At baseline
p-valueaMen, N (%) Women, N (%)
Number 36,094 12,955
HIV acquisition MSM 21,491 (59.5) 110 (0.9)
IDU 5110 (14.2) 2322 (17.9)
Heterosexual 7092 (19.7) 9037 (69.8)
Other/not known 2401 (6.7) 1486 (11.5) 0.0001
Race White 19,017 (52.7) 5795 (44.7)
Black African 2220 (6.2) 2610 (20.2)
Other 920 (2.6) 484 (3.7)
Unknown 13,937 (38.6) 4066 (31.4) 0.0001
Age (years) Median (IQR) 39 (33, 46) 34 (29, 40) 0.0001
BMI (kg/m2) <18 847 (2.4) 707 (5.5)
≥18, ≤26 23,936 (66.3) 7645 (59.0)
>26, ≤30 4602 (12.8) 1368 (10.6)
>30 1223 (3.4) 914 (7.1)
Not known 5486 (15.2) 2321 (17.9) 0.0001
Smoking Current 13,556 (37.6) 3814 (29.4)
Ex- 6465 (17.9) 1841 (14.2)
Never 8186 (22.7) 4800 (37.1)
Not known 7887 (21.9) 2500 (19.3) 0.0001
Prior AIDS diagnosis 8285 (23.0) 2769 (21.4) 0.0002
Exposed to ART 21,954 (60.8) 7813 (60.3) 0.30
CD4 (cells/mm3) Median (IQR) 400 (244, 590) 405 (249, 591) 0.06
HIV RNA (log10 copies/mL) Median (IQR) 3.0 (1.7, 4.6) 2.9 (1.7, 4.2) 0.0001
HIV RNA ≤50 copies/mL 10,499 (29.1) 3565 (27.5) 0.0007
Family history of CVD 2325 (6.4) 718 (5.5) 0.0003
Lipodystrophy 5310 (14.7) 1759 (13.6) 0.002
Diabetes 976 (2.7) 221 (1.7) 0.0001
Bypass 26 (0.1) 1 (0.0) 0.007
Endarterectomy 9 (0.0) 1 (0.0) 0.41
Angioplasty 66 (0.2) 3 (0.0) 0.0001
Any ICP 96 (0.3) 5 (0.0) 0.0001
Receipt of LLD 1241 (3.4) 163 (1.3) 0.0001
TC (mmol/L) Median (IQR) 4.8 (4.0, 5.7) 4.8 (4.0, 5.6) 0.90
TG (mmol/L) Median (IQR) 1.6 (1.1, 2.7) 1.3 (0.9, 1.9) 0.0001
HDL cholesterol (mmol/L) Median (IQR) 1.1 (0.8, 1.3) 1.3 (1.1, 1.6) 0.0001
Dyslipidaemia 13831 (38.3) 3049 (23.5) 0.0001
Systolic blood pressure (mmHg) Median (IQR) 120 (115, 131) 120 (110, 125) 0.0001
Diastolic blood pressure (mmHg) Median (IQR) 80 (70, 84) 75 (70, 80) 0.0001
Receipt of anti-hypertensives 1030 (2.9) 349 (2.7) 0.35
Receipt of ACEIs 621 (1.7) 143 (1.1) 0.0001
Hypertension 3904 (10.8) 904 (7.0) 0.0001
Haemoglobin Median (IQR) 9.0 (8.4, 9.5) 7.9 (7.2, 8.4) 0.0001
eGFR Median (IQR) 104.2 (89.5, 121.4) 108.8 (88.9, 135.8) 0.0001
Predicted 10-year CVD risk Low (<10%) 9879 (27.4) 4148 (32.0)
Moderate (10% to 20%) 2378 (6.6) 143 (1.1)
High (>20%) 748 (2.1) 22 (0.2)
Unknown 23,089 (64.0) 8642 (66.7) 0.0001
MSM, men who have sex with men; IDU, intravenous drug use; BMI, body mass index; ART, anti-retroviral therapy; CVD, cardiovascular disease;
ICPs, invasive cardiovascular procedures; LLDs, lipid lowering drugs; TC, total cholesterol; TG, triglycerides; HDL cholesterol, High-density lipopro-
tein cholesterol; ACEIs, Angiotensin-converting enzyme inhibitors; eGFR, estimated glomerular filtration rate.ap < 0.05.
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4 | DISCUSSION
Women generally have a lower CVD risk than men, particu-
larly at younger ages [10–16]. While an increased risk of CVD
in HIV-positive individuals is well recognized [1–8], this
increased risk has been noted to be more pronounced in HIV-
positive women than in HIV-positive men [2–4,8,9]. To the
best of our knowledge, however, this is the first study to
specifically investigate gender differences in the management
of CVD between HIV-positive women and men, with substan-
tial follow-up time and rigorously monitored and centrally vali-
dated events and interventions. In our study, we observed
that women had a lower overall CVD risk at baseline, that
blood pressure was more likely to be monitored in women,
and that initiation rates of CVD interventions were generally
lower in women than in men. This was also true for most
CVD interventions when analyses were restricted to periods
of follow-up during which each person was at high CVD risk.
In fully adjusted models, women were less likely than men to
receive LLDs, ACEIs and ICPs, although conversely were more
likely to receive anti-hypertensives.
We identified subgroups of study participants who we
believed would be considered to be at higher CVD risk and in
whom monitoring and interventions for CVD might be appro-
priate. Where women were deemed to be at high CVD risk,
this was most commonly due to the presence of hypertension
and/or triglyceridemia, or because of older age. The relatively
high proportion of time that women spent with hypertension
likely reflects the higher proportion of those of black African
ethnicity, a known risk factor for hypertension [41], among
women than men. When restricting the analysis only to peri-
ods of follow-up during which an individual was in one of the
high CVD risk subgroups, women generally had lower initia-
tion rates than men for most CVD interventions. Among
younger, pre-menopausal women, it would not be surprising to
see lower initiation rates, reflecting the lower overall CVD
risk. However, as women age, their CVD risk becomes more
similar to that of men [10–16] and thus we might have
expected more similar initiation rates of CVD interventions in
the older age group. While only a relatively low proportion of
follow-up time among women was contributed by those with a
CVD risk score >10%, a higher proportion of follow-up time
in women could not be categorized due to missing data on
Table 2. Total duration of follow-up (person-years) spent by
men and women in one of seven high CVD risk subgroupsa
High CVD risk group Men, N (%) Women, N (%)
Total 314,843 (100.0) 113,821 (100.0)
TC > 6.2 mmol/L (>240 mg/dL) 44,629 (14.2) 15,224 (13.4)
TG > 2.3 mmol/L (>204 mg/dL) 92,397 (29.3) 16,917 (14.9)
Hypertension 75,035 (23.8) 19,195 (16.9)
Previous MI 4206 (1.3) 359 (0.0)
Diabetes 17,226 (5.5) 4170 (3.7)
Age > 50 years 99,911 (31.7) 19,866 (17.5)
CVD risk score >10% 86,425 (27.5) 4990 (4.4)
CVD, cardiovascular disease; TC, total cholesterol; TG, triglycerides;
MI, myocardial infarction.
aProportions are not mutually exclusive.
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Figure 1. Unadjusted rates of initiation (/100 PYRS) of CVD interventions in women and men, total follow-up period.
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one or more components of the score. Hence, this “high-risk”
category may miss women with a genuinely high risk who had
not been identified as such. Although the initiation rates of
LLDs, ACEIs and anti-hypertensives for women with a CVD
risk score >10% were higher in women than for men, we do
not think that we can focus solely on this high risk group, as
the other separate high CVD risk indicators should also
prompt concern about high CVD risk. Furthermore, these
unadjusted rates did not take into account differences in other
characteristics.
In fully adjusted models, women in our study were less
likely than men to receive LLDs, ACEIs and ICPs, and of these
interventions least likely to receive ICPs. Several other studies
from the general population have also demonstrated that
women are less likely to receive diagnostic and therapeutic
invasive CVD-interventions than men [11,12,16,20,30–34],
and that women have higher mortality after invasive proce-
dures [16,27–29]. Women are less likely to have ST-elevation
myocardial infarction and more likely to have either none or
atypical symptoms at the time of MI [42–46], possibly partly
explained by female-specific characteristics in macro-and
microvasculature [47–49]. For stroke, women tend to present
with more generalized symptoms such as dizziness, headache,
disorientation and changes in consciousness as well as other
atypical symptoms compared to men [16]. These more subtle
and heterogeneous clinical presentations, in addition to poten-
tial gender-related differences in diagnostic biomarkers and
social factors, may complicate and/or delay the diagnosis and
management of MI and stroke in women [16,32,33,42,50–53].
Furthermore, at the time of MI and stroke, women also tend
to be older, to have more severe CVD risk profiles and more
comorbidities [10–16,42,54] than men, which may also
complicate interventions and contribute to a poorer prognosis.
Finally, lesser use of invasive CVD-interventions in women
may also be due to differences in angiographic features;
women are not always eligible for treatment with stents or
grafts due to microvascular rather than obstructive coronary
disease, as well as lesser degree of carotid stenosis which is
less suitable for stenting [16,31,49].
In contrast to the receipt of LLDs, ACEIs and ICPs, women in
our study were more likely to receive anti-hypertensives than
men. The increased use of anti-hypertensives appeared to be
driven by women with hypertension and a CVD risk score
>10%. As ACEIs are partly used as anti-hypertensives, the gen-
der difference in the use of ACEIs was expectedly reduced after
controlling for hypertension, and the difference between men
and women was less marked when the combined class of anti-
hypertensives or ACEIs was considered, with the lower uptake
in women for ACEIs being counter-balanced by the higher
uptake of anti-hypertensives in this group. Supported by the
slightly higher monitoring rates for blood pressure that we
observed in women, our findings argue that hypertension might
have more focus in clinical practice. This may relate to hyperten-
sion being one of the more common CVD risk factors in women
[42,54], to increased monitoring among pregnant women and
women on contraceptives, as well as the relatively large propor-
tion of women being of black African origin.
4.1 | Limitations
While we capture information on many CVD risk factors,
some CVD risk factors and preventive CVD-interventions (e.g.
smoking cessation in smokers, advice on diet, exercise and the
use of over-the-counter drugs such as aspirin) as well as some
0.1 1.0 10.0
Relative Rate and 95% CI
 Unadjusted  Adjusted
RR       95% CI        p-value
ICPs
Anti-hypertensives
ACEIs
LLDs
0.53          0.50, 0.57         0.0001
0.83          0.78, 0.88         0.0001
0.63          0.58, 0.67         0.0001
0.93          0.86, 1.01         0.07
0.81          0.76, 0.86         0.0001
1.17          1.10, 1.25         0.0001
0.26          0.21, 0.32         0.0001
0.54          0.43, 0.68         0.0001
Figure 2. Relative rates of receipt of CVD interventions in women compared to men. Multivariate model adjusted for: Age, calendar year,
body mass index, total cholesterol, triglycerides, hypertension, previous myocardial infarction, race, smoking status, AIDS, cardiovascular dis-
ease (CVD) family history, stroke, diabetes and CVD risk score >10% (individuals having a moderate or high Framingham CVD risk score).
CVD, cardiovascular disease; RR, relative rate; 95% CI, 95% confidence interval; LLDs, lipid lowering drugs; ACEIs, Angiotensin-converting
enzyme inhibitors; ICPs, invasive cardiovascular procedures. *p < 0.05.
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female-specific factors (e.g. pregnancy, menopausal status, hor-
mone supplementation and contraceptives) are not captured in
our dataset. For this reason, we did not aim to identify specific
individuals in whom interventions would be certain to be rec-
ommended or to assess whether any such recommendations
were appropriate, but simply used the data to identify groups
at higher CVD risk in whom awareness of CVD risk and regu-
lar monitoring should be greater. It is possible that some indi-
viduals may not have accepted any interventions they were
offered, or that provider or health system-related factors, (e.g.
availability of specialized cardiac care), may have influenced
our results, possibilities we are unable to investigate due to
the nature of the dataset. Although we believe that our
detailed query processes and monitoring activities contribute
to minimize ascertainment bias, we cannot exclude the possibil-
ity that there may be under- or delayed-ascertainment of the
receipt of CVD interventions or that this information may be
less readily available in women than men. A relatively small
proportion of follow-up time among women was contributed
by those at moderate or high CVD risk, but still represented
around 5000 PYRS, and our results suggest that the study is
not under-powered to detect effects. Finally, although the dif-
ferences observed are intriguing, we are unable to investigate
the reasons for these gender differences.
5 | CONCLUSION
In our study, HIV-positive women were less likely than men to
receive most CVD-related interventions, with the exception of
anti-hypertensive drugs. These findings are mostly consistent
with those from the general population.
The reasons why women are less likely to receive interven-
tions than men are multiple, but insufficient monitoring and
awareness of CVD risk in women, and the more heteroge-
neous clinical presentations of CVD probably play a major
role. As HIV-positive individuals in general are at higher risk
of CVD further efforts are needed to ensure that both
women and men are appropriately monitored for CVD risk
and, if required, receive relevant CVD-related interventions.
Furthermore studies are warranted on why these gender
related differences exist in the prevention and management of
CVD in HIV-positive individuals.
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J Weel. Medisch Spectrum Twente, Enschede: GJ Kootstra¤, CE Delsing, M van
der Burg-van de Plas, H Heins, E Lucas. Noorwest Ziekenhuisgroep, Alkmaar: W
Kortmann¤, G van Twillert¤, JWT Cohen Stuart, BMW Diederen, D Pronk, FA
van Truijen-Oud, WA van der Reijden, R Jansen. OLVG, Amsterdam: K Brinkman
¤, GEL van den Berk, WL Blok, PHJ Frissen, KD Lettinga, WEM Schouten, J
Veenstra, CJ Brouwer, GF Geerders, K Hoeksema, MJ Kleene, IB van der Meche,
M Spelbrink, H Sulman, AJM Toonen, S Wijnands, M Damen, D Kwa, E Witte.
Radboudumc, Nijmegen: PP Koopmans, M Keuter, AJAM van der Ven, HJM ter
Hofstede, ASM Dofferhoff, R van Crevel, M Albers, MEW Bosch, KJT Grintjes-
Huisman, BJ Zomer, FF Stelma, J Rahamat-Langendoen, D Burger. Rijnstate, Arn-
hem: C Richter¤, EH Gisolf, RJ Hassing, G ter Beest, PHM van Bentum, N Lange-
beek, R Tiemessen, CMA Swanink. Spaarne Gasthuis, Haarlem: SFL van Lelyveld
¤, R Soetekouw, N Hulshoff, LMM van der Prijt, J van der Swaluw, N Bermon,
WA van der Reijden, R Jansen, BL Herpers, D Veenendaal. Medisch Centrum Jan
van Goyen, Amsterdam: DWM Verhagen, M van Wijk. St Elisabeth Ziekenhuis,
Tilburg: MEE van Kasteren¤, AE Brouwer, BAFM de Kruijf-van de Wiel, M Kui-
pers, RMWJ Santegoets, B van der Ven, JH Marcelis, AGM Buiting, PJ Kabel.
Universitair Medisch Centrum Groningen, Groningen: WFW Bierman¤, H Schol-
vinck, KR Wilting, Y Stienstra, H de Groot-de Jonge, PA van der Meulen, DA de
Weerd, J Ludwig-Roukema, HGM Niesters, A Riezebos-Brilman, CC van Leer-
Buter, M Knoester. Universitair Medisch Centrum Utrecht, Utrecht: AIM Hoepel-
man¤, T Mudrikova, PM Ellerbroek, JJ Oosterheert, JE Arends, RE Barth, MWM
Wassenberg, EM Schadd, DHM van Elst-Laurijssen, EEB van Oers-Hazelzet, S
Vervoort, M van Berkel, R Schuurman, F Verduyn-Lunel, AMJ Wensing. VUmc,
Amsterdam: EJG Peters¤, MA van Agtmael, M Bomers, J de Vocht, M Heitmuller,
LM Laan, AM Pettersson, CMJE Vandenbroucke-Grauls, CW Ang . Wilhelmina
Kinderziekenhuis, UMCU, Utrecht: SPM Geelen, TFW Wolfs, LJ Bont, N Nauta.
COORDINATING CENTRE P Reiss, DO Bezemer, AI van Sighem, C Smit, FWNM
Wit, TS Boender, S Zaheri, M Hillebregt, A de Jong, D Bergsma, P Hoekstra, A de
Lang, S Grivell, A Jansen, MJ Rademaker, M Raethke, R Meijering, S Schn€orr, L
de Groot, M van den Akker, Y Bakker, E Claessen, A El Berkaoui, J Koops, E Krui-
jne, C Lodewijk, L Munjishvili, B Peeck, C Ree, R Regtop, Y Ruijs, T Rutkens, L van
de Sande, M Schoorl, A Timmerman, E Tuijn, L Veenenberg, S van der Vliet, A
Wisse, T Woudstra, B Tuk.
AQUITA INE COHORT (FRANCE )
COMPOS IT ION DU CONSE I L SC I ENT IF IQUE
Coordination: F Bonnet, F Dabis
Scientific committee: M Dupon, V Gaborieau, D Lacoste, D Malvy, P Mercie,
P Morlat, D Neau, JL Pellegrin, S Tchamgoue, E Lazaro, C Cazanave, M Vanden-
hende, MO Vareil, Y Gerard, P Blanco, S Bouchet, D Breilh, H Fleury, I Pellegrin,
G Che^ne, R Thiebaut, L Wittkop, L Wittkop, O Leleux, S Lawson-Ayayi, A Gim-
bert, S Desjardin, L Lacaze-Buzy, V Petrov-Sanchez
Epidemiology and Methodology: F Bonnet, G Che^ne, F Dabis, R Thiebaut, L
Wittkop
Infectious Diseases and Internal Medicine: K Andre, N Bernard, F Bonnet, O
Caubet, L Caunegre, C Cazanave, I Chossat, C Courtault, FA Dauchy, S De
Witte, D Dondia, M Dupon, P Duffau, H Dutronc, S Farbos, I Faure, H Ferrand,
V Gaborieau, Y Gerard, C Greib, M Hessamfar, Y Imbert, D Lacoste, P Lataste,
E Lazaro, D Malvy, J Marie, M Mechain, P Mercie, E Monlun, P Morlat, D Neau,
A Ochoa, JL Pellegrin, T Pistone, I Raymond, MC Receveur, P Rispal, L Sorin, S
Tchamgoue, C Valette, MA Vandenhende, MO Vareil, JF Viallard, H Wille, G
Wirth.
Immunology: I Pellegrin, P Blanco
Virology: H Fleury, ME Lafon, P Trimoulet, P Bellecave, C Tumiotto
Pharmacology: S Bouchet, D Breilh, F Haramburu, G Miremeont-Salame
Data collection, Project Management and Statistical Analyses: MJ Blaizeau,
M Decoin, C Hannapier, E Lenaud et A Pougetoux; S Delveaux, C D’Ivernois, F
Diarra, B Uwamaliya-Nziyumvira, O Leleux; F Le Marec, E Boerg, S Lawson-
Ayayi;
IT department and eCRF development: G Palmer, V Conte, V Sapparrart
AHOD (AUSTRAL IAN H IV OBSERVAT IONAL DATABASE ,
AUSTRAL IA )
Central coordination: M Law*, K Petoumenos, R Puhr, R Huang (Sydney, New
South Wales). Participating physicians (city, state): R Moore, S Edwards, J Hoy,
K Watson, N Roth, H Lau (Melbourne, Victoria); M Bloch, D Baker, A Carr, D
Cooper, (Sydney, New South Wales); M O’Sullivan (Gold Coast, Queensland), D
Nolan, G Guelfi (Perth, Western Australia).
BASS ( SPA IN )
Central coordination: G Calvo, F Torres, S Mateu (Barcelona);
Participating physicians (city): P Domingo, MA Sambeat, J Gatell, E Del
Cacho, J Cadafalch, M Fuster (Barcelona); C Codina, G Sirera, A Vaque
(Badalona).
THE BRUSSELS ST P IERRE COHORT (BELG IUM)
Coordination: S De Wit*, N Clumeck, M Delforge, C Necsoi.
Participating physicians: N Clumeck, S De Wit*, AF Gennotte, M Gerard, K
Kabeya, D Konopnicki, A Libois, C Martin, MC Payen, P Semaille, Y Van
Laethem.
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CPCRA (USA )
Central coordination: J Neaton, G Bartsch, WM El-Sadr*, E Krum, G Thompson,
D Wentworth;
Participating physicians (city, state): R Luskin-Hawk (Chicago, Illinois); E Telzak
(Bronx, New York); WM El-Sadr (Harlem, New York); DI Abrams (San Francisco,
California); D Cohn (Denver, Colorado); N Markowitz (Detroit, Michigan); R Arduino
(Houston, Texas); D Mushatt (New Orleans, Louisiana); G Friedland (New Haven,
Connecticut); G Perez (Newark, New Jersey); E Tedaldi (Philadelphia, Pennsylvania);
E Fisher (Richmond,Virginia); F Gordin (Washington, DC); LR Crane (Detroit, Michi-
gan); J Sampson (Portland, Oregon); J Baxter (Camden, New Jersey).
EUROS IDA (MULT INAT IONAL )
Steering Committee: J Gatell, B Gazzard, A Horban, I Karpov, M Losso, A d’Ar-
minio Monforte, C Pedersen, M Ristola, A Phillips, P Reiss, J Lundgren, J Rock-
stroh
Chair: J Rockstroh
Study Co-leads: A Mocroft, O Kirk
Coordinating Centre Staff: O Kirk, L Peters, C Matthews, AH Fischer, A
Bojesen, D Raben, D Kristensen, K Grønborg Laut, JF Larsen, D Podlekareva
Statistical Staff: A Mocroft, A Phillips, A Cozzi-Lepri, L Shepherd, A Schultze,
S Amele
The multi-centre study group, EuroSIDA (national coordinators in parenthesis).
Argentina: (M Losso), M Kundro, Hospital JM Ramos Mejia, Buenos Aires.
Austria: (B Schmied), Pulmologisches Zentrum der Stadt Wien, Vienna; R
Zangerle, Medical University Innsbruck, Innsbruck.
Belarus: (I Karpov), A Vassilenko, Belarus State Medical University, Minsk,
VM Mitsura, Gomel State Medical University, Gomel; D Paduto, Regional AIDS
Centre, Svetlogorsk.
Belgium: (N Clumeck), S De Wit, M Delforge, Saint-Pierre Hospital, Brussels;
E Florence, Institute of Tropical Medicine, Antwerp; L Vandekerckhove, Univer-
sity Ziekenhuis Gent, Gent.
Bosnia-Herzegovina: (V Hadziosmanovic), Klinicki Centar Univerziteta Sara-
jevo, Sarajevo.
Croatia: (J Begovac), University Hospital of Infectious Diseases, Zagreb.
Czech Republic: (L Machala), D Jilich, Faculty Hospital Bulovka, Prague; D
Sedlacek, Charles University Hospital, Plzen.
Denmark: G Kronborg, T Benfield, Hvidovre Hospital, Copenhagen; J Ger-
stoft, T Katzenstein, Rigshospitalet, Copenhagen; NF Møller, C Pedersen,
Odense University Hospital, Odense; L Ostergaard, Skejby Hospital, Aarhus, L
Wiese, Roskilde Hospital, Roskilde; LN Nielsen, Hillerod Hospital, Hillerod.
Estonia: (K Zilmer), West-Tallinn Central Hospital, Tallinn; Jelena Smidt,
Nakkusosakond Siseklinik, Kohtla-J€arve.
Finland: (M Ristola), I Aho, Helsinki University Central Hospital, Helsinki.
France: (J-P Viard), Ho^tel-Dieu, Paris; P-M Girard, Hospital Saint-Antoine,
Paris; C Pradier, E Fontas, Ho^pital de l’Archet, Nice; C Duvivier, Ho^pital Necker-
Enfants Malades, Paris.
Germany: (J Rockstroh), Universit€ats Klinik Bonn; R Schmidt, Medizinische
Hochschule Hannover; O Degen, University Medical Center Hamburg-Eppen-
dorf, Infectious Diseases Unit, Hamburg; HJ Stellbrink, IPM Study Center, Ham-
burg; C Stefan, JW Goethe University Hospital, Frankfurt; J Bogner,
Medizinische Poliklinik, Munich; G F€atkenheuer, Universit€at K€oln, Cologne.
Georgia: (N Chkhartishvili) Infectious Diseases, AIDS & Clinical Immunology
Research Center, Tbilisi
Greece: (P Gargalianos), G Xylomenos, K Armenis, Athens General Hospital
“G Gennimatas”; H Sambatakou, Ippokration General Hospital, Athens.
Hungary: (J Szlavik), Szent Laslo Hospital, Budapest.
Iceland: (M Gottfredsson), Landspitali University Hospital, Reykjavik.
Ireland: (F Mulcahy), St. James’s Hospital, Dublin.
Israel: (I Yust), D Turner, M Burke, Ichilov Hospital, Tel Aviv; E Shahar, G Has-
soun, Rambam Medical Center, Haifa; H Elinav, M Haouzi, Hadassah University
Hospital, Jerusalem; D Elbirt, ZM Sthoeger, AIDS Center (Neve Or), Jerusalem.
Italy: (A d’Arminio Monforte), Istituto Di Clinica Malattie Infettive e Tropicale,
Milan; R Esposito, I Mazeu, C Mussini, Universita Modena, Modena; F Mazzotta,
A Gabbuti, Ospedale S Maria Annunziata, Firenze; V Vullo, M Lichtner, University
di Roma la Sapienza, Rome; M Zaccarelli, A Antinori, R Acinapura, M Plazzi, Isti-
tuto Nazionale Malattie Infettive Lazzaro Spallanzani, Rome; A Lazzarin, A Cas-
tagna, N Gianotti, Ospedale San Raffaele, Milan; M Galli, A Ridolfo, Osp. L. Sacco,
Milan.
Latvia: (B Rozentale), Infectology Centre of Latvia, Riga.
Lithuania: (V Uzdaviniene) Vilnius University Hospital Santariskiu Klinikos, Vil-
nius; R Matulionyte, Center of Infectious Diseases, Vilnius University Hospital San-
tariskiu Klinikos,Vilnius.
Luxembourg: (T Staub), R Hemmer, Centre Hospitalier, Luxembourg.
Netherlands: (P Reiss), Academisch Medisch Centrum bij de Universiteit van
Amsterdam, Amsterdam.
Norway: (V Ormaasen), A Maeland, J Bruun, Ulleval Hospital, Oslo.
Poland: (B Knysz), J Gasiorowski, M Inglot, Medical University, Wroclaw; A
Horban, E Bakowska, Centrum Diagnostyki i Terapii AIDS, Warsaw; R Flisiak, A
Grzeszczuk, Medical University, Bialystok; M Parczewski, K Maciejewska, B
Aksak-Was, Medical Univesity, Szczecin; M Beniowski, E Mularska, Osrodek
Diagnostyki i Terapii AIDS, Chorzow; T Smiatacz, M Gensing, Medical University,
Gdansk; E Jablonowska, E Malolepsza, K Wojcik, Wojewodzki Szpital Specjalisty-
czny, Lodz; I Mozer-Lisewska, Poznan University of Medical Sciences, Poznan.
Portugal: (L Caldeira), Hospital Santa Maria, Lisbon; K Mansinho, Hospital de
Egas Moniz, Lisbon; F Maltez, Hospital Curry Cabral, Lisbon.
Romania: (R Radoi), C Oprea, Spitalul de Boli Infectioase si Tropicale: Dr. Vic-
tor Babes, Bucarest.
Russia: (A Panteleev), O Panteleev, St Petersburg AIDS Centre, St Peterburg; A
Yakovlev, Medical Academy Botkin Hospital, St Petersburg; T Trofimora, Novgorod
Centre for AIDS, Novgorod, I Khromova, Centre for HIV/AIDS & and Infectious
Diseases, Kaliningrad; E Kuzovatova, Nizhny Novgorod Scientific and Research
Institute of Epidemiology and Microbiology named after Academician I.N. Blokhina,
Nizhny Novogrod; E Borodulina, E Vdoushkina, Samara State Medical University,
Samara.
Serbia: (D Jevtovic), The Institute for Infectious and Tropical Diseases, Bel-
grade.
Slovenia: (J Tomazic), University Clinical Centre Ljubljana, Ljubljana.
Spain: (JM Gatell), JM Miro, Hospital Clinic Universitari de Barcelona, Barce-
lona; S Moreno, JM Rodriguez, Hospital Ramon y Cajal, Madrid; B Clotet, A Jou,
R Paredes, C Tural, J Puig, I Bravo, Hospital Germans Trias i Pujol, Badalona; P
Domingo, M Gutierrez, G Mateo, M Sambeat, Hospital Sant Pau, Barcelona; JM
Laporte, Hospital Universitario de Alava, Vitoria-Gasteiz.
Sweden: (K Falconer), A Thalme, A Sonnerborg, Karolinska University Hospi-
tal, Stockholm; A Blaxhult, Venh€alsan-Sodersjukhuset, Stockholm; L Flamholc,
Malm€o University Hospital, Malm€o.
Switzerland: (A Scherrer), R Weber, University Hospital Zurich; M Cavassini,
University Hospital Lausanne; A Calmy, University Hospital Geneva; H Furrer,
University Hospital Bern; M Battegay, University Hospital Basel; P Schmid, Can-
tonal Hospital St. Gallen.
Ukraine: A Kuznetsova, Kharkov State Medical University, Kharkov; G Kysely-
ova, Crimean Republican AIDS centre, Simferopol; M Sluzhynska, Lviv Regional
HIV/AIDS Prevention and Control CTR, Lviv.
United Kingdom: (B Gazzard), St. Stephen’s Clinic, Chelsea and Westminster
Hospital, London; AM Johnson, E Simons, S Edwards, Mortimer Market Centre, Lon-
don; A Phillips, MA Johnson, A Mocroft, Royal Free and University College Medical
School, London (Royal Free Campus); C Orkin, Royal London Hospital, London; J
Weber, G Scullard, Imperial College School of Medicine at St. Mary’s, London; A
Clarke, Royal Sussex County Hospital, Brighton; C Leen, Western General Hospital,
Edinburgh.
The following centers have previously contributed data to EuroSIDA:
Infectious Diseases Hospital, Sofia, Bulgaria.
Ho^pital de la Croix Rousse, Lyon, France.
Ho^pital de la Pitie-Salpetiere, Paris, France.
Unite INSERM, Bordeaux, France.
Ho^pital Edouard Herriot, Lyon, France.
Bernhard Nocht Institut f€ur Tropenmedizin, Hamburg, Germany.
1st I.K.A Hospital of Athens, Athens, Greece.
Ospedale Riuniti, Divisione Malattie Infettive, Bergamo, Italy.
Ospedale di Bolzano, Divisione Malattie Infettive, Bolzano, Italy.
Ospedale Cotugno, III Divisione Malattie Infettive, Napoli, Italy.
Derer Hospital, Bratislava, Slovakia.
Hospital Carlos III, Departamento de Enfermedades Infecciosas, Madrid,
Spain.
Kiev Centre for AIDS, Kiev, Ukraine.
Luhansk State Medical University, Luhansk, Ukraine.
Odessa Region AIDS Center, Odessa, Ukraine.
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HIVB IVUS (SWEDEN )
Central coordination: L Morfeldt, G Thulin, A Sundstr€om.
Participating physicians (city): B Akerlund (Huddinge); K Koppel, A Karlsson
(Stockholm); L Flamholc, C Hakangard (Malm€o).
THE ICONA FOUNDAT ION ( I TALY )
BOARD OF D IRECTORS
A d’Arminio Monforte (President), A Antinori, A Castagna, F Castelli, R Cauda, G
Di Perri, M Galli, R Iardino, G Ippolito, GC Marchetti, CF Perno, F von Schloes-
ser, P Viale
SC IENT IF IC SECRETARY
A d’Arminio Monforte, A Antinori, A Castagna, F Ceccherini-Silberstein, A Cozzi-
Lepri, E Girardi, S Lo Caputo, C Mussini, M Puoti
STEER ING COMMITTEE
M Andreoni, A Ammassari, A Antinori, C Balotta, A Bandera, P Bonfanti, S Bonora, M
Borderi, A Calcagno, L Calza, MR Capobianchi, A Castagna, F Ceccherini-Silberstein,
A Cingolani, P Cinque, A Cozzi-Lepri, A d’Arminio Monforte, A De Luca, A Di Biagio,
E Girardi, N Gianotti, A Gori, G Guaraldi, G Lapadula, M Lichtner, S Lo Caputo, G
Madeddu, F Maggiolo, G Marchetti, S Marcotullio, L Monno, C Mussini, S Nozza, M
Puoti, E Quiros Roldan, R Rossotti, S Rusconi, MM Santoro, A Saracino, M Zaccarelli.
STAT I ST ICAL AND MONITOR ING TEAM
A Cozzi-Lepri, I Fanti, L Galli, P Lorenzini, A Rodano, M Shanyinde, A Tavelli
B IOLOG ICAL BANK INMI
F Carletti, S Carrara, A Di Caro, S Graziano, F Petrone, G Prota, S Quartu, S
Truffa
PART IC IPAT ING PHYS IC IANS AND CENTERS
Italy A Giacometti, A Costantini, V Barocci (Ancona); G Angarano, L Monno, C San-
toro (Bari); F Maggiolo, C Suardi (Bergamo); P Viale, V Donati, G Verucchi
(Bologna); F Castelli, C Minardi, E Quiros Roldan (Brescia); T Quirino, C Abeli
(Busto Arsizio); PE Manconi, P Piano (Cagliari); B Cacopardo, B Celesia (Catania);
J Vecchiet, K Falasca (Chieti); A Pan, S Lorenzotti (Cremona); L Sighinolfi, D Segala
(Ferrara); F Mazzotta, F Vichi (Firenze); G Cassola, C Viscoli, A Alessandrini, N
Bobbio, G Mazzarello (Genova); C Mastroianni, V Belvisi (Latina); P Bonfanti, I Car-
amma (Lecco); A Chiodera, P Milini (Macerata); A d’Arminio Monforte, M Galli, A
Lazzarin, G Rizzardini, M Puoti, A Castagna, G Marchetti, MC Moioli, R Piolini, AL
Ridolfo, S Salpietro, C Tincati, (Milano); C Mussini, C Puzzolante (Modena); A Gori,
G Lapadula (Monza); N Abrescia, A Chirianni, G Borgia, R Orlando, G Bonadies, F
Di Martino, I Gentile, L Maddaloni (Napoli); AM Cattelan, S Marinello (Padova); A
Cascio, C Colomba (Palermo); F Baldelli, E Schiaroli (Perugia); G Parruti, F Sozio
(Pescara); G Magnani, MA Ursitti (Reggio Emilia); M Andreoni, A Antinori, R
Cauda, A Cristaudo, V Vullo, R Acinapura, G Baldin, M Capozzi, S Cicalini, A Cin-
golani, L Fontanelli Sulekova, G Iaiani, A Latini, I Mastrorosa, MM Plazzi, S Savinelli,
A Vergori (Roma); M Cecchetto, F Viviani (Rovigo); G Madeddu, P Bagella (Sas-
sari); A De Luca, B Rossetti (Siena); A Franco, R Fontana Del Vecchio (Siracusa); D
Francisci, C Di Giuli (Terni); P Caramello, G Di Perri, S Bonora, GC Orofino, M
Sciandra (Torino); M Bassetti, A Londero (Udine); G Pellizzer, V Manfrin (Vicenza),
G Starnini, A Ialungo (Viterbo).
NICE H IV COHORT (FRANCE )
Central coordination: C Pradier*, E Fontas, K Dollet, C Caissotti.
Participating physicians: P Dellamonica, E Bernard, J Courjon, E Cua, F De
Salvador-Guillouet, J Durant, C Etienne, S Ferrando, V Mondain-Miton, A Naqvi,
I Perbost, S Pillet, B Prouvost-Keller, P Pugliese, V Rio, K Risso, PM Roger.
SHCS ( SWISS H IV COHORT STUDY , SWITZERLAND )
The data are gathered by the Five Swiss University Hospitals, two Cantonal Hospi-
tals, 15 affiliated hospitals and 36 private physicians (listed in http://www.shcs.ch/
180-health-care-providers).
MEMBERS OF THE SWISS H IV COHORT STUDY
V Aubert, M Battegay, E Bernasconi, J B€oni, DL Braun, Hc Bucher , A Calmy, M
Cavassini, A Ciuffi, G Dollenmaier, M Egger, L Elzi, J Fehr, J Fellay, H Furrer
(Chairman of the Clinical and Laboratory Committee), CA Fux, HF G€unthard
(President of the SHCS), D Haerry (deputy of “Positive Council”), B Hasse, HH
Hirsch, M Hoffmann, I H€osli, C Kahlert, L Kaiser, O Keiser, T Klimkait, RD
Kouyos, H Kovari,B Ledergerber, G Martinetti, B Martinez de Tejada, C Mar-
zolini, KJ Metzner, N M€uller, D Nicca, G Pantaleo, P Paioni, A Rauch (Chairman
of the Scientific Board), C Rudin (Chairman of the Mother & Child Substudy),
AU Scherrer (Head of Data Centre), P Schmid, R Speck, M St€ockle, P Tarr, A
Trkola, P Vernazza, G Wandeler, R Weber*, S Yerly.
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